Clinical Trials Browser

Phase 1/2 × Lymphoma, B-Cell × ixazomib × Clear all

NCT02898259 2022-09-26

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Phase 1/2 Terminated

19 enrolled 15 charts

Lymphoma, Lymphoma, B-Cell

NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Phase 1/2 Unknown

38 enrolled 12 charts

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse